Xenetic Biosciences (NASDAQ:XBIO), a biopharmaceutical company which focuses on the research and development of biologic drugs and novel oncology therapeutics, recently received an update from its partner, Shire (NASDAQ:SHPG). Shire's drug, SHP656, which treats Hemophilia A, did not meet the study's primary objective, but Xenetic's promising PolyXen technology, licensed to Shire, was further validated in this trial. I'll outline to investors the disappointing news from Shire and why Xenetic's PolyXen technology is still in high demand. Also, I'll detail investors about Xenetic's promising non-partnered pipeline, like its XBIO-101 drug.
Xenetic is a thinly traded, very small biopharmaceutical company of less than 10 employees. The company is located in Lexington, MA, and is right across the street to one of the leading drug companies in the world, Shire. Located below is the company's internal development plans, along with its partnered programs.
